<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><description>It takes nothing to join the crowd, but it takes everything to stand alone</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 11 Apr 2021 07:23:47 +0800</pubDate><image><url>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</url><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>替雷利珠单抗注射液 申请上市技术审评报告</title><link>https://mp.weixin.qq.com/s/Yd3-3pB9H8rZmap28z7Tzw</link><description></description><content:encoded><![CDATA[替雷利珠单抗注射液 申请上市技术审评报告]]></content:encoded><pubDate>Sat, 10 Apr 2021 20:40:17 +0800</pubDate></item><item><title>图说：看干细胞如何保护人体八大系统</title><link>https://mp.weixin.qq.com/s/5y5zCkQDkr3YZldJv37Xhg</link><description></description><content:encoded><![CDATA[图说：看干细胞如何保护人体八大系统]]></content:encoded><pubDate>Sat, 10 Apr 2021 20:40:17 +0800</pubDate></item><item><title>生物药研发注册申报及质量研究</title><link>https://mp.weixin.qq.com/s/c4kvc6FFJkjJXP3AsCXkEA</link><description></description><content:encoded><![CDATA[生物药研发注册申报及质量研究]]></content:encoded><pubDate>Sat, 10 Apr 2021 20:40:17 +0800</pubDate></item><item><title>乳腺癌靶向药物的研究及临床应用新进展</title><link>https://mp.weixin.qq.com/s/jrVzkltbPIdIqF6kOFQf2A</link><description></description><content:encoded><![CDATA[乳腺癌靶向药物的研究及临床应用新进展]]></content:encoded><pubDate>Fri, 09 Apr 2021 21:10:56 +0800</pubDate></item><item><title>CDK4/6靶向药：七大问题，范蕾教授为您一次解答！</title><link>https://mp.weixin.qq.com/s/x6oTk2Jbfxd-JyjW8zid0w</link><description></description><content:encoded><![CDATA[CDK4/6靶向药：七大问题，范蕾教授为您一次解答！]]></content:encoded><pubDate>Fri, 09 Apr 2021 21:10:56 +0800</pubDate></item><item><title>图解｜一图读懂《化妆品分类规则和分类目录》</title><link>https://mp.weixin.qq.com/s/L1d26urhY1EkDl3sOdWUPA</link><description></description><content:encoded><![CDATA[图解｜一图读懂《化妆品分类规则和分类目录》]]></content:encoded><pubDate>Fri, 09 Apr 2021 21:10:56 +0800</pubDate></item><item><title>CAR-T新药跑步上市，国内研发竞赛如火如荼</title><link>https://mp.weixin.qq.com/s/l-XT9zjm739GSIXUlJ7AzQ</link><description></description><content:encoded><![CDATA[CAR-T新药跑步上市，国内研发竞赛如火如荼]]></content:encoded><pubDate>Fri, 09 Apr 2021 21:10:56 +0800</pubDate></item><item><title>2021年中国mRNA治疗行业研究报告</title><link>https://mp.weixin.qq.com/s/F8Hms_HlCwNbklqdou6-6g</link><description></description><content:encoded><![CDATA[2021年中国mRNA治疗行业研究报告]]></content:encoded><pubDate>Thu, 08 Apr 2021 22:21:00 +0800</pubDate></item><item><title>药物研发中如何确定创新药及仿制药杂质限度</title><link>https://mp.weixin.qq.com/s/bjRbXSDcKva91Z2eXeH6XA</link><description></description><content:encoded><![CDATA[药物研发中如何确定创新药及仿制药杂质限度]]></content:encoded><pubDate>Thu, 08 Apr 2021 22:21:00 +0800</pubDate></item><item><title>特异靶向KRAS-G12C突变的抗肿瘤药物研究进展</title><link>https://mp.weixin.qq.com/s/oEl-YptuZfmQ--Ey-K_r_Q</link><description></description><content:encoded><![CDATA[特异靶向KRAS-G12C突变的抗肿瘤药物研究进展]]></content:encoded><pubDate>Thu, 08 Apr 2021 22:21:00 +0800</pubDate></item><item><title>基因治疗制品申报IND/NDA药学评价要点</title><link>https://mp.weixin.qq.com/s/yJZ5YBPw189A75p5-X-4Nw</link><description></description><content:encoded><![CDATA[基因治疗制品申报IND/NDA药学评价要点]]></content:encoded><pubDate>Wed, 07 Apr 2021 20:31:22 +0800</pubDate></item><item><title>药物是怎样从研发到上市的？</title><link>https://mp.weixin.qq.com/s/dP-_iM106ZISuXq0k8_FpQ</link><description></description><content:encoded><![CDATA[药物是怎样从研发到上市的？]]></content:encoded><pubDate>Wed, 07 Apr 2021 20:31:22 +0800</pubDate></item><item><title>研发过程数据可靠性的管理与思考</title><link>https://mp.weixin.qq.com/s/9cr32G68XBg4bp9Gs5BS8w</link><description></description><content:encoded><![CDATA[研发过程数据可靠性的管理与思考]]></content:encoded><pubDate>Wed, 07 Apr 2021 20:31:22 +0800</pubDate></item><item><title>阿达木单抗注射液申请上市技术审评报告</title><link>https://mp.weixin.qq.com/s/SJIR3LjdD9zgS5B8ck5CPw</link><description></description><content:encoded><![CDATA[阿达木单抗注射液申请上市技术审评报告]]></content:encoded><pubDate>Tue, 06 Apr 2021 22:16:44 +0800</pubDate></item><item><title>Nature：抗体偶联药开发概览及市场预测</title><link>https://mp.weixin.qq.com/s/WQLVX5486xqHMqzoM5tYgw</link><description></description><content:encoded><![CDATA[Nature：抗体偶联药开发概览及市场预测]]></content:encoded><pubDate>Tue, 06 Apr 2021 22:16:44 +0800</pubDate></item><item><title>新药研发流程及研发项目管理时间轴</title><link>https://mp.weixin.qq.com/s/v08Mgllfh00vKBhvkuoywg</link><description></description><content:encoded><![CDATA[新药研发流程及研发项目管理时间轴]]></content:encoded><pubDate>Tue, 06 Apr 2021 22:16:44 +0800</pubDate></item><item><title>小分子药物的困境与出路</title><link>https://mp.weixin.qq.com/s/chgUWeUnNrNrwr1eaZCwPw</link><description></description><content:encoded><![CDATA[小分子药物的困境与出路]]></content:encoded><pubDate>Mon, 05 Apr 2021 17:27:42 +0800</pubDate></item><item><title>CDE：ADC药物PK研究要点</title><link>https://mp.weixin.qq.com/s/oORWE9owDyNXJk9srSdQrA</link><description></description><content:encoded><![CDATA[CDE：ADC药物PK研究要点]]></content:encoded><pubDate>Mon, 05 Apr 2021 17:27:42 +0800</pubDate></item><item><title>化学原料药杂质研究与控制策略</title><link>https://mp.weixin.qq.com/s/_13n3hi470v568AD0UaZjQ</link><description></description><content:encoded><![CDATA[化学原料药杂质研究与控制策略]]></content:encoded><pubDate>Mon, 05 Apr 2021 17:27:42 +0800</pubDate></item><item><title>梳理 | 2类创新药行业报告汇总</title><link>https://mp.weixin.qq.com/s/zm2Bsa9TrDppMa7bkq79Mg</link><description></description><content:encoded><![CDATA[梳理 | 2类创新药行业报告汇总]]></content:encoded><pubDate>Thu, 01 Apr 2021 20:34:06 +0800</pubDate></item></channel></rss>